TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Trial of a Lung-Open Ventilation Strategy in Acute Lung Injury
Brief Summary: A multinational, randomized trial comparing two lung protecting strategies of respiratory life support among critically ill patients with severe lung injury.


Options:
A: Intervention Type: DEVICE; Name: High-frequency oscillation; Assigned to Arm(s): N/A | Intervention Type: DEVICE; Name: Conventional lung-open mechanical ventilation; Assigned to Arm(s): N/A
B: Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: High-frequency Oscillation and Tracheal Gas Insufflation | Intervention Type: OTHER; Name: High-frequency Oscillation and Tracheal Gas Insufflation; Assigned to Arm(s): 1
C: Arm Label: Conventional Ventilation; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Lung Protective Ventilation | Arm Label: High Frequency Oscillation; Type: EXPERIMENTAL; Interventions: Device: SensorMedics 3100B High Frequency Oscillatory Ventilator | Intervention Type: DEVICE; Name: SensorMedics 3100B High Frequency Oscillatory Ventilator; Assigned to Arm(s): High Frequency Oscillation | Intervention Type: PROCEDURE; Name: Lung Protective Ventilation; Assigned to Arm(s): Conventional Ventilation
D: Intervention Type: PROCEDURE; Name: Control Ventilation Strategy; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Trial of a Lung-Open Ventilation Strategy in Acute Lung Injury
Brief Summary: A multinational, randomized trial comparing two lung protecting strategies of respiratory life support among critically ill patients with severe lung injury.


Options:
A: Arm Label: One Group; Type: N/A; Interventions: N/A
B: Intervention Type: PROCEDURE; Name: Control Ventilation Strategy; Assigned to Arm(s): N/A
C: Arm Label: A; Type: EXPERIMENTAL; Interventions: Procedure: prone position | Arm Label: B; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: prone position; Assigned to Arm(s): A
D: Arm Label: PHARLAP ventilation group; Type: EXPERIMENTAL; Interventions: Other: PHARLAP mechanical ventilation strategy | Arm Label: Control group ventilation; Type: ACTIVE_COMPARATOR; Interventions: Other: Control group mechanical ventilation strategy | Intervention Type: OTHER; Name: PHARLAP mechanical ventilation strategy; Assigned to Arm(s): PHARLAP ventilation group | Intervention Type: OTHER; Name: Control group mechanical ventilation strategy; Assigned to Arm(s): Control group ventilation

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Trial of a Lung-Open Ventilation Strategy in Acute Lung Injury
Brief Summary: A multinational, randomized trial comparing two lung protecting strategies of respiratory life support among critically ill patients with severe lung injury.


Options:
A: Intervention Type: PROCEDURE; Name: Control Ventilation Strategy; Assigned to Arm(s): N/A
B: Arm Label: One Group; Type: N/A; Interventions: N/A
C: Intervention Type: OTHER; Name: Recruitment maneuver; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Other: Different Mechanical Ventilation Protocols | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: Different Mechanical Ventilation Protocols | Intervention Type: OTHER; Name: Different Mechanical Ventilation Protocols; Assigned to Arm(s): 1, 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Trial of a Lung-Open Ventilation Strategy in Acute Lung Injury
Brief Summary: A multinational, randomized trial comparing two lung protecting strategies of respiratory life support among critically ill patients with severe lung injury.


Options:
A: Arm Label: EPVent; Type: EXPERIMENTAL; Interventions: Procedure: Placement of an esophageal balloon measurements, Other: Transpulmonary pressure-directed ventilation (EPVent) | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Placement of an esophageal balloon measurements, Other: Low tidal volume ventilation | Intervention Type: PROCEDURE; Name: Placement of an esophageal balloon measurements; Assigned to Arm(s): Control, EPVent | Intervention Type: OTHER; Name: Low tidal volume ventilation; Assigned to Arm(s): Control | Intervention Type: OTHER; Name: Transpulmonary pressure-directed ventilation (EPVent); Assigned to Arm(s): EPVent
B: Arm Label: Albuterol Sulfate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Albuterol Sulfate, Procedure: Mini-Bronchoalveolar Lavage (BAL) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Mini-Bronchoalveolar Lavage (BAL), Drug: Placebo | Intervention Type: DRUG; Name: Albuterol Sulfate; Assigned to Arm(s): Albuterol Sulfate | Intervention Type: PROCEDURE; Name: Mini-Bronchoalveolar Lavage (BAL); Assigned to Arm(s): Albuterol Sulfate, Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Minimal alveolar distension; Type: ACTIVE_COMPARATOR; Interventions: Device: Setting of positive end-expiratory pressure | Arm Label: Maximal alveolar distension; Type: EXPERIMENTAL; Interventions: Device: Setting of positive end-expiratory pressure | Intervention Type: DEVICE; Name: Setting of positive end-expiratory pressure; Assigned to Arm(s): Maximal alveolar distension, Minimal alveolar distension
D: Intervention Type: PROCEDURE; Name: Control Ventilation Strategy; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Study of the Effectiveness of Specialist Oncology Nursing Case Management in Improving Continuity of Supportive Cancer Care in the Community (SONICS)
Brief Summary: This research project will address the issue of gaps in continuity of supportive care for cancer patients during the early phases of the disease trajectory that result in unmet needs and unnecessary morbidity. The investigators intend to study the impact of a specialized cancer-nursing program, Interlink Community Cancer Nurses (Interlink) on patient outcomes. Impact will be assessed directly using a validated measure of continuity of care from the patients' perspective and validated measures of key supportive care patient outcomes including unmet needs, distress, uncertainty in illness, and quality of life, in a randomized trial.


Options:
A: Arm Label: breast cancer radiation therapy; Type: N/A; Interventions: N/A
B: Arm Label: Intervention group; Type: EXPERIMENTAL; Interventions: Behavioral: Mini-AFTERc | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Mini-AFTERc; Assigned to Arm(s): Intervention group
C: Arm Label: intervention group; Type: ACTIVE_COMPARATOR; Interventions: Device: distress thermometer | Arm Label: control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: distress thermometer; Assigned to Arm(s): intervention group
D: Intervention Type: BEHAVIORAL; Name: Community Interlink Program; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Study of the Effectiveness of Specialist Oncology Nursing Case Management in Improving Continuity of Supportive Cancer Care in the Community (SONICS)
Brief Summary: This research project will address the issue of gaps in continuity of supportive care for cancer patients during the early phases of the disease trajectory that result in unmet needs and unnecessary morbidity. The investigators intend to study the impact of a specialized cancer-nursing program, Interlink Community Cancer Nurses (Interlink) on patient outcomes. Impact will be assessed directly using a validated measure of continuity of care from the patients' perspective and validated measures of key supportive care patient outcomes including unmet needs, distress, uncertainty in illness, and quality of life, in a randomized trial.


Options:
A: Arm Label: 1 frequent control; Type: ACTIVE_COMPARATOR; Interventions: Procedure: CT-scan, CEA, X-ray of lungs | Arm Label: 2 less frequent control; Type: OTHER; Interventions: Procedure: CT-scan, CEA, X-ray of lungs | Intervention Type: PROCEDURE; Name: CT-scan, CEA, X-ray of lungs; Assigned to Arm(s): 1 frequent control | Intervention Type: PROCEDURE; Name: CT-scan, CEA, X-ray of lungs; Assigned to Arm(s): 2 less frequent control
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Other: ca coli follow-up by GP | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: ca coli follow-up by GP | Intervention Type: OTHER; Name: ca coli follow-up by GP; Assigned to Arm(s): 1, 2
C: Intervention Type: BEHAVIORAL; Name: Community Interlink Program; Assigned to Arm(s): N/A
D: Arm Label: minimal surveillance; Type: OTHER; Interventions: Other: surveillance program after completion of primary treatment | Arm Label: intensive surveillance; Type: OTHER; Interventions: Other: surveillance program after completion of primary treatment | Intervention Type: OTHER; Name: surveillance program after completion of primary treatment; Assigned to Arm(s): intensive surveillance, minimal surveillance

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Study of the Effectiveness of Specialist Oncology Nursing Case Management in Improving Continuity of Supportive Cancer Care in the Community (SONICS)
Brief Summary: This research project will address the issue of gaps in continuity of supportive care for cancer patients during the early phases of the disease trajectory that result in unmet needs and unnecessary morbidity. The investigators intend to study the impact of a specialized cancer-nursing program, Interlink Community Cancer Nurses (Interlink) on patient outcomes. Impact will be assessed directly using a validated measure of continuity of care from the patients' perspective and validated measures of key supportive care patient outcomes including unmet needs, distress, uncertainty in illness, and quality of life, in a randomized trial.


Options:
A: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Other: Intervention | Arm Label: Attention; Type: EXPERIMENTAL; Interventions: Other: Attention | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Other: Control | Intervention Type: OTHER; Name: Intervention; Assigned to Arm(s): Intervention | Intervention Type: OTHER; Name: Attention; Assigned to Arm(s): Attention | Intervention Type: OTHER; Name: Control; Assigned to Arm(s): Control
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Meaning Centered Group Psychotherapy | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Supportive Group Psychotherapy | Intervention Type: BEHAVIORAL; Name: Meaning Centered Group Psychotherapy; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Supportive Group Psychotherapy; Assigned to Arm(s): 2
C: Intervention Type: BEHAVIORAL; Name: Community Interlink Program; Assigned to Arm(s): N/A
D: Arm Label: Stepped Care; Type: EXPERIMENTAL; Interventions: Other: Stepped Care | Arm Label: Care as usual; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Stepped Care; Assigned to Arm(s): Stepped Care

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy and Safety of Methylxanthines in Very Low Birthweight Infants
Brief Summary: At least 5 of every 1000 live-born babies are very premature and weigh only 500 to 1250 grams at birth. Approximately 30-40% of these high-risk infants either die or survive with lasting disabilities. The aim of this research is to reduce this heavy burden of illness. A multi-center randomized controlled trial has been designed in which 2000 very low birth weight infants will be enrolled. Our goal is to determine whether the avoidance of methylxanthine drugs will improve survival without disability to 18 months, corrected for prematurity.

Methylxanthine drugs such as caffeine are used to prevent or treat periodic breathing and breath-holding spells in premature infants. However, there is a striking lack of evidence for the long-term efficacy and safety of this therapy. Methylxanthines block a naturally occurring substance, called adenosine, which protects the brain during episodes of oxygen deficiency. Such episodes are common in infants who are treated with methylxanthines. It is possible that methylxanthines may worsen the damage caused by lack of oxygen. Therefore, this trial will clarify whether methylxanthines cause more good than harm in very low birth weight infants.


Options:
A: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Device: NIPPV | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Device: nCPAP | Intervention Type: DEVICE; Name: nCPAP; Assigned to Arm(s): B | Intervention Type: DEVICE; Name: NIPPV; Assigned to Arm(s): A
B: Arm Label: NIMV- nasal respiratory support; Type: EXPERIMENTAL; Interventions: Device: NIMV with SLE ventilator vs HFNC via Vapotherm | Arm Label: HFNC- nasal respiratory support with HFNC; Type: EXPERIMENTAL; Interventions: Device: NIMV with SLE ventilator vs HFNC via Vapotherm | Intervention Type: DEVICE; Name: NIMV with SLE ventilator vs HFNC via Vapotherm; Assigned to Arm(s): HFNC- nasal respiratory support with HFNC, NIMV- nasal respiratory support
C: Arm Label: NSIPPV group; Type: ACTIVE_COMPARATOR; Interventions: Device: NSIPPV | Arm Label: BiPAP group; Type: ACTIVE_COMPARATOR; Interventions: Device: BiPAP | Intervention Type: DEVICE; Name: NSIPPV; Assigned to Arm(s): NSIPPV group | Intervention Type: DEVICE; Name: BiPAP; Assigned to Arm(s): BiPAP group
D: Intervention Type: DRUG; Name: Caffeine citrate injection; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy and Safety of Methylxanthines in Very Low Birthweight Infants
Brief Summary: At least 5 of every 1000 live-born babies are very premature and weigh only 500 to 1250 grams at birth. Approximately 30-40% of these high-risk infants either die or survive with lasting disabilities. The aim of this research is to reduce this heavy burden of illness. A multi-center randomized controlled trial has been designed in which 2000 very low birth weight infants will be enrolled. Our goal is to determine whether the avoidance of methylxanthine drugs will improve survival without disability to 18 months, corrected for prematurity.

Methylxanthine drugs such as caffeine are used to prevent or treat periodic breathing and breath-holding spells in premature infants. However, there is a striking lack of evidence for the long-term efficacy and safety of this therapy. Methylxanthines block a naturally occurring substance, called adenosine, which protects the brain during episodes of oxygen deficiency. Such episodes are common in infants who are treated with methylxanthines. It is possible that methylxanthines may worsen the damage caused by lack of oxygen. Therefore, this trial will clarify whether methylxanthines cause more good than harm in very low birth weight infants.


Options:
A: Arm Label: IntellO2; Type: EXPERIMENTAL; Interventions: Device: IntellO2 | Arm Label: Manual; Type: ACTIVE_COMPARATOR; Interventions: Other: Manual control | Intervention Type: DEVICE; Name: IntellO2; Assigned to Arm(s): IntellO2 | Intervention Type: OTHER; Name: Manual control; Assigned to Arm(s): Manual
B: Arm Label: Automated FiO2 control; Type: EXPERIMENTAL; Interventions: Device: Automated FiO2 Control | Arm Label: Manual Adjustment; Type: PLACEBO_COMPARATOR; Interventions: N/A | Intervention Type: DEVICE; Name: Automated FiO2 Control; Assigned to Arm(s): Automated FiO2 control
C: Arm Label: CLiO2; Type: EXPERIMENTAL; Interventions: Device: Automated oxygen control by the CLiO2 algorithm | Arm Label: Oxygenie; Type: EXPERIMENTAL; Interventions: Device: Automated oxygen control by the Oxygenie algorithm | Intervention Type: DEVICE; Name: Automated oxygen control by the CLiO2 algorithm; Assigned to Arm(s): CLiO2 | Intervention Type: DEVICE; Name: Automated oxygen control by the Oxygenie algorithm; Assigned to Arm(s): Oxygenie
D: Intervention Type: DRUG; Name: Caffeine citrate injection; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy and Safety of Methylxanthines in Very Low Birthweight Infants
Brief Summary: At least 5 of every 1000 live-born babies are very premature and weigh only 500 to 1250 grams at birth. Approximately 30-40% of these high-risk infants either die or survive with lasting disabilities. The aim of this research is to reduce this heavy burden of illness. A multi-center randomized controlled trial has been designed in which 2000 very low birth weight infants will be enrolled. Our goal is to determine whether the avoidance of methylxanthine drugs will improve survival without disability to 18 months, corrected for prematurity.

Methylxanthine drugs such as caffeine are used to prevent or treat periodic breathing and breath-holding spells in premature infants. However, there is a striking lack of evidence for the long-term efficacy and safety of this therapy. Methylxanthines block a naturally occurring substance, called adenosine, which protects the brain during episodes of oxygen deficiency. Such episodes are common in infants who are treated with methylxanthines. It is possible that methylxanthines may worsen the damage caused by lack of oxygen. Therefore, this trial will clarify whether methylxanthines cause more good than harm in very low birth weight infants.


Options:
A: Arm Label: Standard therapy plus Aromatherapy; Type: EXPERIMENTAL; Interventions: Drug: lavender and chamomile essential oils | Arm Label: Standard therapy ALONE; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: lavender and chamomile essential oils; Assigned to Arm(s): Standard therapy plus Aromatherapy
B: Intervention Type: DRUG; Name: Caffeine citrate injection; Assigned to Arm(s): N/A
C: Arm Label: SVS vs Control; Type: EXPERIMENTAL; Interventions: Device: Stochastic Vibrotactile Stimulation (SVS), Other: Control | Intervention Type: DEVICE; Name: Stochastic Vibrotactile Stimulation (SVS); Assigned to Arm(s): SVS vs Control | Intervention Type: OTHER; Name: Control; Assigned to Arm(s): SVS vs Control
D: Arm Label: Low lactose formula; Type: ACTIVE_COMPARATOR; Interventions: Other: Low lactose or regular formula | Arm Label: Regular formula; Type: ACTIVE_COMPARATOR; Interventions: Other: Low lactose or regular formula | Intervention Type: OTHER; Name: Low lactose or regular formula; Assigned to Arm(s): Low lactose formula, Regular formula

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy and Safety of Methylxanthines in Very Low Birthweight Infants
Brief Summary: At least 5 of every 1000 live-born babies are very premature and weigh only 500 to 1250 grams at birth. Approximately 30-40% of these high-risk infants either die or survive with lasting disabilities. The aim of this research is to reduce this heavy burden of illness. A multi-center randomized controlled trial has been designed in which 2000 very low birth weight infants will be enrolled. Our goal is to determine whether the avoidance of methylxanthine drugs will improve survival without disability to 18 months, corrected for prematurity.

Methylxanthine drugs such as caffeine are used to prevent or treat periodic breathing and breath-holding spells in premature infants. However, there is a striking lack of evidence for the long-term efficacy and safety of this therapy. Methylxanthines block a naturally occurring substance, called adenosine, which protects the brain during episodes of oxygen deficiency. Such episodes are common in infants who are treated with methylxanthines. It is possible that methylxanthines may worsen the damage caused by lack of oxygen. Therefore, this trial will clarify whether methylxanthines cause more good than harm in very low birth weight infants.


Options:
A: Intervention Type: DRUG; Name: Caffeine citrate injection; Assigned to Arm(s): N/A
B: Arm Label: Intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Increasing use of Antenatal Corticosteroids (ACS) | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Increasing use of Antenatal Corticosteroids (ACS); Assigned to Arm(s): Intervention
C: Arm Label: Betamethasone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Betamethasone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Betamethasone; Assigned to Arm(s): Betamethasone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: ACS (Group 1); Type: ACTIVE_COMPARATOR; Interventions: Drug: Betamethason Sodium Phosphate | Arm Label: Placebo (Group 2); Type: PLACEBO_COMPARATOR; Interventions: Drug: Normal saline | Intervention Type: DRUG; Name: Betamethason Sodium Phosphate; Assigned to Arm(s): ACS (Group 1) | Intervention Type: DRUG; Name: Normal saline; Assigned to Arm(s): Placebo (Group 2)

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Controlled Trial of Two Hemoglobin Thresholds for Transfusion in Newborns <1000g Birth Weight
Brief Summary: Hypothesis: That a high hemoglobin threshold for transfusion in extremely low birth weight (ELBW) infants is associated with a lower rate of survival without severe morbidity (defined as one or more of retinopathy of prematurity, bronchopulmonary dysplasia, or periventricular leukomalacia/ventriculomegaly).

Primary Objective: To determine whether either a liberal or more restrictive threshold of hemoglobin level for red cell transfusion in ELBW infants is safer, by randomizing to either a high transfusion hemoglobin threshold or a low transfusion hemoglobin threshold.

Follow-up at a corrected age of 18 months represents a conventional age at which to first assess neurodevelopmental outcomes, and to predict long-term outcomes.


Options:
A: Arm Label: Shorter-storage red blood cell units; Type: ACTIVE_COMPARATOR; Interventions: Biological: Red blood cell units stored <= 10 days | Arm Label: Longer-storage red blood cell units; Type: ACTIVE_COMPARATOR; Interventions: Biological: Red blood cell units stored >= 21 days | Intervention Type: BIOLOGICAL; Name: Red blood cell units stored <= 10 days; Assigned to Arm(s): Shorter-storage red blood cell units | Intervention Type: BIOLOGICAL; Name: Red blood cell units stored >= 21 days; Assigned to Arm(s): Longer-storage red blood cell units
B: Arm Label: Biological; Type: EXPERIMENTAL; Interventions: Biological: Transfusion | Arm Label: Standard PRBCs; Type: EXPERIMENTAL; Interventions: Biological: Transfusion | Intervention Type: BIOLOGICAL; Name: Transfusion; Assigned to Arm(s): Biological, Standard PRBCs
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Biological: Standard leukoreduced irradiated blood cell transfusion | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Biological: Washed leukoreduced irradiated blood cell transfusions | Intervention Type: BIOLOGICAL; Name: Standard leukoreduced irradiated blood cell transfusion; Assigned to Arm(s): 1 | Intervention Type: BIOLOGICAL; Name: Washed leukoreduced irradiated blood cell transfusions; Assigned to Arm(s): 2
D: Intervention Type: PROCEDURE; Name: Red blood cell transfusion; Assigned to Arm(s): N/A

Answer: D